PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration
PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration
复制标题
DOI：
10.1007/s13277-014-2118-3
复制
发表时间：
2014-09-01
期刊：
影响因子：
--
通讯作者：
Lou, Wei-ying
中科院分区：
文献类型：
--
作者：
Che, Huan-yong;Guo, Hang-yuan;Lou, Wei-ying
酪氨酸和磷酸肌苷激酶在包括细胞存活和细胞运动在内的许多癌细胞过程的调节中起着至关重要的作用。间变性甲状腺癌（ATC）是一种罕见的致死性甲状腺癌，目前尚无有效的治疗药物。在此，我们研究了PP121（酪氨酸和磷酸肌苷激酶的双重抑制剂）在ATC治疗中的抗癌活性。我们发现PP121能有效抑制细胞活力，诱导细胞凋亡，抑制细胞迁移和侵袭。PP121的潜在抗癌机制可能是其抑制ATC细胞中磷脂酰肌醇3-激酶(PI3K)/Akt信号通路。此外，PP121在体内可有效抑制ATC肿瘤的生长。综上所述，我们的研究表明PP121可能是一种很有前景的ATC治疗化合物，可能为ATC治疗提供新的思路。
The tyrosine and phosphoinositide kinases play crucial roles in the regulation of many cancer cell processes including cell survival and cell motility. Anaplastic thyroid carcinoma (ATC) is a rare and deadly type of thyroid cancer, and so far, there are no effective therapeutic compounds for ATC. Herein, we investigate the anticancer activities of PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, in ATC therapy. We found that PP121 is effective at suppressing cell viability, inducing cell apoptosis, and inhibiting cell migration and invasion. The potential anticancer mechanism for PP121 might be its inhibitory effects on phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways in ATC cells. Furthermore, PP121 is effective at suppressing ATC tumor growth in vivo. In summary, our studies suggest that PP121 might be a promising therapeutic compound for ATC treatment, which might shed new light on ATC therapy.